Keita Minami, Takahiro Osawa, Takahiro Kojima, Tomohiko Hara, Masatoshi Eto, Ario Takeuchi, Yasutomo Nakai, Kosuke Ueda, Michinobu Ozawa, Motohide Uemura, et al. Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment. Urologic oncology. 2023. 41. 11. 458.e9-458.e19
Yasutomo Nakai, Ario Takeuchi, Takahiro Osawa, Takahiro Kojima, Tomohiko Hara, Mikio Sugimoto, Masatoshi Eto, Keita Minami, Kosuke Ueda, Michinobu Ozawa, et al. Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma. Journal of geriatric oncology. 2021. 12. 5. 834-837
Keita Tamura, Takahiro Osawa, Ario Takeuchi, Keita Minami, Yasutomo Nakai, Kosuke Ueda, Michinobu Ozawa, Motohide Uemura, Mikio Sugimoto, Kojiro Ohba, et al. External validation of the albumin, C-reactive protein and lactate dehydrogenase model in patients with metastatic renal cell carcinoma receiving second-line axitinib therapy in a Japanese multi-center cohort. Japanese journal of clinical oncology. 2021. 51. 5. 810-818
Takahiro Osawa, Takahiro Kojima, Tomohiko Hara, Mikio Sugimoto, Masatoshi Eto, Ario Takeuchi, Keita Minami, Yasutomo Nakai, Kosuke Ueda, Michinobu Ozawa, et al. Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma. Cancer science. 2020. 111. 7. 2460-2471
Sei Naito, Tomoyuki Kato, Osamu Ichiyanagi, Takafumi Narisawa, Masayuki Kurokawa, Mayu Yagi, Masaki Ushijima, Michinobu Ozawa, Hidenori Kanno, Yuta Kurota, et al. New prognostic model for synchronous metastatic renal cell carcinoma. International journal of urology : official journal of the Japanese Urological Association. 2020. 27. 5. 448-456